ALZN (STOCKS)
Alzamend Neuro, Inc. Common Stock
$0.881100
+0.023600 (+2.75%)
Prev close: $0.857500
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Stephan Jackman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3.38M
- Employees
- 7
- P/E (TTM)
- -0.20
- P/B (TTM)
- 1.49
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
4
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q3)
|
$-0.58 | $-1.96 | +1.3835 | +70.46% |
|
Dec 2025 (Q2)
|
$-0.30 | $-1.99 | +1.6941 | +84.96% |
|
Sep 2025 (Q1)
|
$-1.28 | $-0.70 | -0.5762 | -81.87% |
|
Mar 2025 (Q3)
|
$-1.71 | $-3.26 | +1.5489 | +47.53% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$6.98K |
| Operating Expenses | $7.03M |
| Research and Development | $3.65M |
| Other Operating Expenses | $3.39M |
| Operating Income/Loss | -$7.03M |
| Income/Loss From Continuing Operations After Tax | -$7.04M |
| Income/Loss From Continuing Operations Before Tax | -$7.04M |
| Interest Expense, Operating | $6.98K |
| Net Income/Loss | $1.97M |
| Net Income/Loss Attributable To Noncontrolling Interest | $9.01M |
| Net Income/Loss Attributable To Parent | -$7.04M |
| Net Income/Loss Available To Common Stockholders, Basic | -$7.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $502.85K |
| Preferred Stock Dividends And Other Adjustments | $502.85K |
| Basic Earnings Per Share | -$3.67 |
| Diluted Earnings Per Share | -$3.67 |
| Basic Average Shares | 3,210,026 |
| Diluted Average Shares | 3,210,026 |
| Assets | $4.04M |
| Current Assets | $3.70M |
| Noncurrent Assets | $342.55K |
| Fixed Assets | $342.55K |
| Liabilities | $1.86M |
| Current Liabilities | $1.86M |
| Noncurrent Liabilities | $0.00 |
| Equity | $2.18M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.18M |
| Liabilities And Equity | $4.04M |
| Net Cash Flow From Operating Activities | -$5.96M |
| Net Cash Flow From Operating Activities, Continuing | -$5.96M |
| Net Cash Flow From Investing Activities | $1.03M |
| Net Cash Flow From Investing Activities, Continuing | $4.01M |
| Net Cash Flow From Financing Activities | $5.52M |
| Net Cash Flow From Financing Activities, Continuing | $5.52M |
| Net Cash Flow | $3.57M |
| Net Cash Flow, Continuing | $3.57M |
| Comprehensive Income/Loss | $1.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $1.97M |
| Other Comprehensive Income/Loss | $0.00 |